ClinicalTrials.gg
TerminatedNCT01837797Updated Oct 17, 2018Results posted

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Phase 3 interventional study of Placebo and Brexpiprazole 1 mg in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Terminated at 2 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated because of recruitment challenges

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
13th of 24
129 · median 189
Started
2013
with 6 others
Phase 3
16 of 24
none open now
Registered
8th of 24
by date
Lead sponsor
4 of 24
H. Lundbeck A/S

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 13th largest by enrollment, is one of 7 that started in 2013, is one of 16 in phase 3, and was the 8th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of brexpiprazole as adjunctive treatment in elderly patients with Major Depressive Disorder (MDD)

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is an outpatient consulting a psychiatrist.
  • The patient has a recurrent Major Depressive Disorder diagnosed according to ™. The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient had at least one previous MDE before the age of 60 years.
  • The patient has a moderate to severe depression and an insufficient response to at least one and no more than three adequate antidepressants treatments.
  • The patient, if a woman, must have had her last natural menstruation ≥24 months prior to the Screening Visit.
  • The patient, if a man, agrees to protocol-defined use of effective if his female partner is of .

Exclusion criteria

Exclusion Criteria:

  • The patient has any current psychiatric disorder or Axis I disorder (™ criteria), established as the primary diagnosis, other than MDD.
  • The patient has a current Axis II (DSM-IV-TR™) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypical or histrionic personality disorder.
  • The patient has experienced/experiences hallucinations, delusions or any psychotic symptomatology in the current MDE.
  • The patient suffers from mental retardation, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient, in the opinion of the investigator, or according to Columbia Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.
  • The patient has had neuroleptic malignant syndrome.
  • The patient has any relevant medical history or current presence of systemic disease.
  • The patient has a neurodegenerative disorder.
  • The patient has, at the Screening Visit an abnormal that is, in the investigator's opinion, .
  • The patient has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, that has not been in remission for >5 years prior to the first dose of IMP.
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)

    Drug: Placebo

  • Experimental
    Brexpiprazole 1 mg

    Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.

    Drug: Brexpiprazole 1 mg

  • Experimental
    Brexpiprazole 3 mg

    Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.

    Drug: Brexpiprazole 3 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Randomisation in Depressive Symptoms During the Randomised Treatment

    Montgomery and Aasberg Depression Rating Scale (MADRS) total score

    Time frame: From randomisation to end of treatment (week 20)

Secondary outcomes

  1. Number of Adverse Events

    15 patients were enrolled to Period 2; only 3 patients completed due to study termination

    Time frame: From randomisation to follow-up (week 24)

  2. Change From Randomisation in Clinical Global Impression During the Randomised Treatment

    Clinical Global Impression - Severity of illness (CGI-S) score

    Time frame: From randomisation to end of treatment (week 20)

  3. Change From Randomisation in Functionality Assessed by SDS During the Randomised Treatment

    Sheehan Disability Scale (SDS) total score

    Time frame: From randomisation to end of treatment (week 20)

  4. Change From Randomisation in Social Adaptation During the Randomised Treatment

    Social Adaptation Self-evaluation Scale (SASS) total score

    Time frame: From randomisation to end of treatment (week 20)

  5. Response During the Randomised Treatment

    Based on a pre-specified decrease in MADRS total score

    Time frame: From randomisation to end of treatment (week 20)

  6. Sustained Response During the Randomised Treatment

    Based on a pre-specified decrease in MADRS total score

    Time frame: From randomisation to end of treatment (week 20)

  7. Remission During the Randomised Treatment

    Based on a pre-specified MADRS total score

    Time frame: From randomisation to end of treatment (week 20)

  8. Sustained Remission During the Randomised Treatment

    Based on a pre-specified MADRS total score

    Time frame: From randomisation to end of treatment (week 20)

  9. Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)

    The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour.

    Time frame: From randomisation to end of treatment (week 20)

07

Results

Posted Mar 3, 2016
Limitations and caveats
Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.

Participant flow

129 patients were enrolled in the study and 128 patients received open-label treatment with one of six commercially available antidepressant antidepressant treatments (ADT) together with double-blind study treatment. Only 15 patients were randomized to Period 2 before the study was terminated; 47 patients entered Period 3.

Period 1
Participant flow — Period 1
MilestonePeriod 1 Placebo and ADTPeriod 2 Placebo and ADTPeriod 2 Brexpiprazole 1 mg and ADTPeriod 2 Brexpiprazole 3 mg and ADTPeriod 3 Placebo and ADT
Started1290000
Completed270000
Not completed1020000
Withdrew: Adverse event90000
Withdrew: Withdrawal by subject60000
Withdrew: Administrative reasons760000
Withdrew: Withdrawal of consent before treatment10000
Withdrew: Other100000
Period 2
Participant flow — Period 2
MilestonePeriod 1 Placebo and ADTPeriod 2 Placebo and ADTPeriod 2 Brexpiprazole 1 mg and ADTPeriod 2 Brexpiprazole 3 mg and ADTPeriod 3 Placebo and ADT
Started06360
Completed01110
Not completed05250
Withdrew: Administrative or other reasons05240
Withdrew: Adverse event00010
Period 3
Participant flow — Period 3
MilestonePeriod 1 Placebo and ADTPeriod 2 Placebo and ADTPeriod 2 Brexpiprazole 1 mg and ADTPeriod 2 Brexpiprazole 3 mg and ADTPeriod 3 Placebo and ADT
Started000047
Completed000024
Not completed000023
Withdrew: Adverse event00001
Withdrew: Administrative reasons000020
Withdrew: Other00002

Outcome measures

SecondaryNumber of Adverse Events

15 patients were enrolled to Period 2; only 3 patients completed due to study termination

Time frame:
From randomisation to follow-up (week 24)
Reported as:
Number · Adverse events
Number of Adverse Events
Adverse eventsPeriod 2 Placebo and ADTPeriod 2 Brexpiprazole 1 mg and ADTPeriod 2 Brexpiprazole 3 mg and ADT
Number of Adverse Events352
PrimaryChange From Randomisation in Depressive Symptoms During the Randomised Treatment

Montgomery and Aasberg Depression Rating Scale (MADRS) total score

Time frame:
From randomisation to end of treatment (week 20)

No measurements were reported for this outcome.

SecondaryChange From Randomisation in Clinical Global Impression During the Randomised Treatment

Clinical Global Impression - Severity of illness (CGI-S) score

Time frame:
From randomisation to end of treatment (week 20)

No measurements were reported for this outcome.

SecondaryChange From Randomisation in Functionality Assessed by SDS During the Randomised Treatment

Sheehan Disability Scale (SDS) total score

Time frame:
From randomisation to end of treatment (week 20)

No measurements were reported for this outcome.

SecondaryChange From Randomisation in Social Adaptation During the Randomised Treatment

Social Adaptation Self-evaluation Scale (SASS) total score

Time frame:
From randomisation to end of treatment (week 20)

No measurements were reported for this outcome.

SecondaryResponse During the Randomised Treatment

Based on a pre-specified decrease in MADRS total score

Time frame:
From randomisation to end of treatment (week 20)

No measurements were reported for this outcome.

SecondarySustained Response During the Randomised Treatment

Based on a pre-specified decrease in MADRS total score

Time frame:
From randomisation to end of treatment (week 20)

No measurements were reported for this outcome.

SecondaryRemission During the Randomised Treatment

Based on a pre-specified MADRS total score

Time frame:
From randomisation to end of treatment (week 20)

No measurements were reported for this outcome.

SecondarySustained Remission During the Randomised Treatment

Based on a pre-specified MADRS total score

Time frame:
From randomisation to end of treatment (week 20)

No measurements were reported for this outcome.

SecondaryNumber of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)

The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour.

Time frame:
From randomisation to end of treatment (week 20)
Reported as:
Number · participants
Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
participantsPeriod 2 Placebo and ADTPeriod 2 Brexpiprazole 1 mg and ADTPeriod 2 Brexpiprazole 3 mg and ADT
No suicidal ideation or behaviour634
Any non-suicidal self-injurious behavior000
Suicidal Ideation002
Preparatory action towards imminent suicidal behav000
Not fatal suicide attempt000
Completed suicide000

Adverse events

Collected over From randomization to follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 2 Placebo and ADT—0/6 (0%)2/6 (33.3%)
Period 2 Brexpiprazole 1 mg and ADT—0/3 (0%)2/3 (66.7%)
Period 2 Brexpiprazole 3 mg and ADT—0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventPeriod 2 Placebo and ADTPeriod 2 Brexpiprazole 1 mg and ADTPeriod 2 Brexpiprazole 3 mg and ADT
Gait disturbanceGeneral disorders0/61/30/6
Weight increasedInvestigations0/61/30/6
DizzinessNervous system disorders0/61/30/6
TremorNervous system disorders0/61/30/6
DyspnoeaRespiratory, thoracic and mediastinal disorders0/61/30/6
Accidental overdoseInjury, poisoning and procedural complications1/60/30/6
Parkinson's diseaseNervous system disorders0/60/31/6
BruxismPsychiatric disorders1/60/30/6
InsomniaPsychiatric disorders0/60/31/6
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/60/30/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Period 2 Placebo and ADTPeriod 2 Brexpiprazole 1 mg and ADTPeriod 2 Brexpiprazole 3 mg and ADTTotal
<=18 years0000
Between 18 and 65 years0000
>=65 years63615
Sex: Female, Male
Sex: Female, Male(Participants)Period 2 Placebo and ADTPeriod 2 Brexpiprazole 1 mg and ADTPeriod 2 Brexpiprazole 3 mg and ADTTotal
Female32611
Male3104
08

Study locations

2 sites
  • US001
    National City, California 91950, United States
  • US008
    Orlando, Florida 32806, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2013
First posted
Apr 23, 2013
Start
Apr 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Mar 3, 2016
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01837797
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Apr 23, 2013
Start date
Apr 2013
Primary completion
May 2014
Completion
May 2014
Results posted
Mar 3, 2016
Last update
Oct 17, 2018

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion